Sidedness of Colorectal Cancer Impacts Risk of Second Primary Gastrointestinal Malignancy

  • Kristy K. Broman
  • Christina E. Bailey
  • Alexander A. ParikhEmail author
Colorectal Cancer



A history of colorectal cancer (CRC) increases the risk of subsequent gastrointestinal (GI) cancer. Cancers of the right colon, left colon, and rectum differ according to molecular profiles, responses to treatment, and outcomes.


The purpose of this study was to determine if CRC location is associated with differential risk for secondary primary GI malignancy.


A retrospective cohort of adults with CRC was compiled using the Surveillance, Epidemiology, and End Results database (1973–2015). Standardized incidence ratios (SIRs) for second primary GI malignancies were compared based on location of the index CRC (right colon, left colon, or rectum).


The cohort included 281,413 adults with CRC (30.3% right, 35.3% left, 34.3% rectum). With a median 4.9-year follow-up, 12,064 (4.3%) patients developed a second primary GI malignancy (64% CRC, 36% non-CRC). Those with CRC at any location had higher than expected incidences of small intestine, bile duct, and other CRCs, and lower incidences of liver and gallbladder cancer. The SIR for small intestinal cancer was higher after right colon cancer than after left colon or rectal cancer. The esophageal cancer SIR was higher after left colon cancer. Pancreas cancer was higher than expected for right colon cancer, but lower for left colon and rectal cancer.


The location of CRC leads to differences in the incidence and location of second primary GI malignancies and may be related to similarities in the associated carcinogenesis and molecular pathways or response to treatment. CRC location not only impacts treatment response and outcomes, but should also be considered during subsequent surveillance.



  1. 1.
    Morton LM, Savage SA, Bhatia S. Multiple primary cancers. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2017.Google Scholar
  2. 2.
    Allemani C, Weir HK, Carreira H, et al. The CONCORD working group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385(9972):977–1010.Google Scholar
  3. 3.
    Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH Publication no. 05-5302. Bethesda: National Cancer Institute.Google Scholar
  4. 4.
    Burt RW. Colon cancer screening. Gastroenterology. 2000;119(3):837–853.CrossRefGoogle Scholar
  5. 5.
    Shussman N, Wexner S. Colorectal polyps and polyposis syndromes. Gastroenterology Report. 2014;2(1):1–15.CrossRefGoogle Scholar
  6. 6.
    6Bufill J. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–788.CrossRefGoogle Scholar
  7. 7.
    Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13:63–69.CrossRefGoogle Scholar
  8. 8.
    Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer. JAMA Oncology. 2017;3(2):211–219.CrossRefGoogle Scholar
  9. 9.
    Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumor location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;10:87–98.CrossRefGoogle Scholar
  10. 10.
    Arnold D, Lueza B, Douillard J-Y, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–1729.CrossRefGoogle Scholar
  11. 11.
    Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance) [abstract no. 3504]. 2016 ASCO annual meeting; 3–7 June 2016: Chicago, IL.Google Scholar
  12. 12.
    Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664–3672.CrossRefGoogle Scholar
  13. 13.
    Ulivi P, Scarpi E, Chiadini E, et al. Right- vs left-sided metastatic colorectal cancer: differences in tumor biology and bevacizumab efficacy. Int J Mol Sci. 2017;18(6):1240.CrossRefGoogle Scholar
  14. 14.
    Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170.CrossRefGoogle Scholar
  15. 15.
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission (
  16. 16.
    Multiple Primary and Histology Coding Rules. National Cancer Institute. Surveillance Epidemiology and End Results Program. Published 1 Jan 2007. Bethesda, MD. Accessed 12 Jun 2018.
  17. 17.
    US Population Data—1969–2016. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Released December 2017. Accessed 27 Jul 2018.
  18. 18.
    Guan X, Jin Y, Chen Y, et al. The incidence characteristics of secondary primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS One. 2015;10(11):E0143067.CrossRefGoogle Scholar
  19. 19.
    Kauffman RM, Wang L, Phillips S, Idrees K, Merchant N, Parikh A. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol. 2014;21:3422–3428.CrossRefGoogle Scholar
  20. 20.
    National Comprehensive Cancer Network. Colon Cancer (Version 2.2018). Accessed 27 July 2018.
  21. 21.
    Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biopsy: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15(3): 411–419.CrossRefGoogle Scholar
  22. 22.
    Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470–6478.CrossRefGoogle Scholar
  23. 23.
    McCredie M, Macfarlane GJ, Bell J, Coates M. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972–1991. Cancer Epidemiol Biomarker Prev. 1997. 6(3):155–160.Google Scholar
  24. 24.
    Neugut AI, Santos J. The association between cancers of the small and large bowel. Cancer Epidemiol Biomarker Prev. 1993;2(6):551–553.Google Scholar
  25. 25.
    Bojesen RD, Riis LB, Hogdall E, Neilsen OH, Jess T. Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study. Clin Gastroenterol Hepatol. 2017;15(12):1900–1907.CrossRefGoogle Scholar
  26. 26.
    Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol. 2005;100:703–710.CrossRefGoogle Scholar
  27. 27.
    Reddy BS, Wynder EL. Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst. 1973;50:1437–1442.CrossRefGoogle Scholar
  28. 28.
    Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarker Prev. 1998;7(3):243–251.Google Scholar
  29. 29.
    Woodford-Richens AK, Rowan AJ, Gorman R, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microstallite instability pathway. Proc Natl Acad Sci U S A. 2001;98(17):9719–9723.CrossRefGoogle Scholar
  30. 30.
    Solovaara R, Roth S, Loukola A, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut. 2002;51:56–59.CrossRefGoogle Scholar
  31. 31.
    Howden CW, Hornung CA. A systematic review of the association between Barrett’s esophagus and colon neoplasms. Am J Gastroenterol. 1995;90(10):1814–1819.Google Scholar
  32. 32.
    Siersema PD, Yu S, Sahbaie P. Colorectal neoplasia in veterans is associated with Barrett’s esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc. 2006;63(40):581–586.CrossRefGoogle Scholar
  33. 33.
    Jorgensen T, Rafaelsen S. Gallstones and colorectal cancer—there is a relationship, but it is hardly due to cholecystectomy. Dis Colon Rectum. 1992;35(1):24CrossRefGoogle Scholar
  34. 34.
    Shabanzadeh DM, Sorensen LT, Jorgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 2017;152(8):1965–1974.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Kristy K. Broman
    • 1
  • Christina E. Bailey
    • 1
  • Alexander A. Parikh
    • 2
    Email author
  1. 1.Division of Surgical OncologyVanderbilt University Medical CenterNashvilleUSA
  2. 2.Division of Surgical OncologyEast Carolina University Brody School of MedicineGreenvilleUSA

Personalised recommendations